Push Admin

Pfizer gets $1.95 billion to produce coronavirus vaccine by year’s end

Article (news)

Noah Weiland, Denise Grady and David E. Sanger, The New York Times

WASHINGTON — As nations around the world race to lock up coronavirus vaccines even before they are ready, the Trump administration on Wednesday made one of largest investments yet, announcing a nearly $2 billion contract with Pfizer and a German biotechnology company for 100 million doses by December.The contract is part of what the White House calls the Warp Speed project, an effort to drastically shorten the time it would take to manufacture and distribute a working vaccine. So far, the United States has put money into more than a half dozen efforts, hoping to build manufacturing ability for an eventual breakthrough.Europe has a parallel effort underway. Germany recently took a 23 percent stake in a German firm, CureVac, that President Donald Trump once tried to lure to American shores in hopes that its vaccine, if successful, would be distributed in the United States first. A European-led fundraising effort in May brought $8 billion in pledges from the world’s governments, philanthropists and leaders for coronavirus vaccine research, even with the United States sitting out the conference.China, meantime, has <a href="https://news.abs-cbn.com/overseas/06/30/20/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china">militarized the effort</a>: Researchers associated with the Academy of Military Medical Sciences have developed one of China’s leading vaccine candidates, and another Chinese firm, Sinopharm Group, announced in June that it was beginning Phase 3 trials in the United Arab Emirates. The Pfizer contract, an agreement to ensure the pharmaceutical giant has a market for its work, is the biggest splash yet by the Americans. If the vaccine being produced by Pfizer and BioNTech, the German firm, proves to be safe and effective in clinical trials, the companies say they could manufacture those first 100 million doses by the end of the year.Under the arrangement, the federal government would obtain that first batch for $1.95 billion, or about $20 a dose, with the rights to acquire up to 500 million more, or 600 million total. Americans would receive the vaccine for free. Before it could be distributed, it would need emergency approval by the Food and Drug Administration. But the US government does not pay the nearly $2 billion until the drug is approved and the first 100 million doses are delivered.Pfizer said that large-scale safety and efficacy trials were to begin this month, with regulatory review set for as early as October, although nothing was guaranteed.“Depending on success in clinical trials, today’s agreement will enable the delivery of approximately 100 million doses of vaccine being developed by Pfizer and BioNTech,” Alex Azar, the health secretary, said in a statement announcing the deal.On Monday, Pfizer and AstraZeneca, a British-Swedish drug company developing a potential vaccine with Oxford University, released data suggesting that their vaccines could stimulate strong immune responses with only minor side effects.But unlike AstraZeneca, which has also obtained funding from the US government, Pfizer did not receive a contract for its earlier research and development efforts — only for the doses and their distribution.By refusing funding until now, Pfizer was able to avoid drawn-out contractual negotiations and get its vaccine to trials, company officials say.“We didn’t accept the federal government funding solely for the reason that we wanted to be able to move as quickly as possible with our vaccine candidate into the clinic,” John Young, Pfizer’s chief business officer, said on Tuesday at a congressional hearing with executives from five vaccine manufacturers.Pfizer and BioNTech are developing a vaccine candidate that uses genetic material from the virus, known as messenger RNA, to stimulate the immune system without making the recipient sick. The technology can create a vaccine quickly, but has not yet produced one that has been approved and marketed.Moderna, a Massachusetts biotech company, received $483 million from the US government for its vaccine development and is also using mRNA technology. By putting the might of an industry giant behind it, Pfizer is making the technology mainstream.<ul class="op-related-articles">	<li><a href="https://news.abs-cbn.com/overseas/07/15/20/moderna-vaccine-induced-antibodies-in-all-trial-participants-paper">Moderna vaccine induced antibodies in all trial participants: paper</a></li></ul>The lack of a track record has prompted some skepticism about the mRNA approach, but Dr. Kathrin Jansen, a senior vice president and the head of vaccine research and development at Pfizer, dismissed the criticism.“That’s not a scientific mindset — that just because it’s new, it will fail,” she said in an interview.Jansen said Pfizer had placed its bet on mRNA not just because the technology could produce a vaccine quickly, but also because its review of previous work by BioNTech on experimental cancer vaccines suggested the approach could cause a powerful immune response. Before the coronavirus pandemic, the two companies had been collaborating on flu vaccines.Vaccines using mRNA consist of genetic material from part of the virus, encased in tiny particles made of fat that help it get into human cells. The mRNA then prompts the cells to churn out a tiny piece of the virus, causing the immune system to attack the real virus if the person is exposed. In essence, the patient’s cells become factories for a harmless fragment of the virus.These mRNA vaccines set off several different kinds of immune responses, Jansen said, which is important because scientists do not know yet which type will be most potent against the coronavirus.Jansen described making an mRNA vaccine as a clean, fast process that required a relatively small footprint to produce many doses.“mRNA has the potential to be fast to produce a product that is very well defined and very pure,” she said.Several other companies are also making mRNA vaccines, and each has its own formulation of the genetic material and types of fat used to encase it.The large vaccine studies set to begin this month will each include 30,000 people, with some getting placebo shots. The Food and Drug Administration has said that to be considered effective, a coronavirus vaccine should protect 50 percent of the people who receive it.Companies hope to show proof of effectiveness by the fall, but that will depend on enrolling enough volunteers in areas where the infection rate is high enough to see a significant difference between the vaccinated people and the placebo group.“We think we will see the end points, given that the infection rates are going up, up, up,” Jansen said. “If the stars are aligned, it could be next fall. But everything has to be right.”<div> c.2020 The New York Times Company </div>

As nations around the world race to lock up coronavirus vaccines even before they are ready, the Trump administration on Wednesday made one of largest investments yet, announcing a nearly $2 billion contract with Pfizer and a German biotechnology company for 100 million doses by December.

As nations around the world race to lock up coronavirus vaccines even before they are ready, the Trump administration on Wednesday made one of largest investments yet, announcing a nearly $2 billion contract with Pfizer and a German biotechnology company for 100 million doses by December.

Pfizer gets $1.95 billion to produce coronavirus vaccine by year’s end

News

Entertainment

Lifestyle

Sports

Metro.Style

More

Traffic

Manila

Horoscope

Business

Pfizer gets $1.95 billion to produce coronavirus vaccine by year’s end

Noah Weiland,

Denise Grady and David E. Sanger,

The New York Times

Published Jul 23, 2020 09:15 AM PHT

Read More:

The New York Times

US

Germany

Trump

coronavirus

coronavirus vaccine

coronavirus when

coronavirus vaccine 2020

COVID-19

coronavirus updates

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.